Development history
In 2020
American and Japanese invention patents of SM-1 project have been authorized; The SM-1 project obtained the ethical approval and officially launched the clinical research. Zhenxing Pharmaceutical completed the first round of financing.
In 2019
The SM-1 project was approved for clinical trial; The BTK inhibitor (Ⅱ) project completed the clinical study.
In 2018
China invention patent of STAT3 and BTK inhibitor (Ⅱ) project was authorized; Application for clinical trial was submitted for SM-1 project.
In 2016
BTK inhibitor (Ⅱ) project approval.
In 2014
SM-1 project was approved by The "Collaborative Innovation Plan" of Shenzhen Science and Technology Innovation Commission. The SM-1 project started pre-clinical study; Shenzhen Zhenxing Pharmaceutical Technology Co. LTD.
In 2013
Dongguan Zhenxing Beite Pharmaceutical Technology Co., LTD was established. STAT-3 inhibitor project approved.
In 2012
The SM-1 project has been approved by the National "12th Five-Year plan" "Major New Drug Innovation and Development" science and technology major special project "Candidate compound Research"
In 2010
Domestic invention patent of SM-1 project is authorized.
In 2009
The SM-1 compound was screened out.
In 2007
Concentrated superior resources, started the research and development of new targeted small-molecule anti-tumor drugs, and committed to the development of original drugs with independent intellectual property rights.
